Binds G-actin monomers. Promotes angiogenesis, reduces inflammation at injury sites, activates satellite cells for muscle repair.
Off-label compounding use for injury recovery, wound healing, cardiac support. Clinical trial evidence is for topical use only.
Organ transplant recipients. Active autoimmune diseases. Active malignancy.
Phase II trials were TOPICAL (corneal drops, wound dressings) — NOT systemic injection as commonly used in compounding. RegeneRx clinical program stalled.
- 1.Goldstein et al., Ann NY Acad Sci 2012 — cardiac repair review across multiple models (preclinical)
- 2.Sosne et al., Cornea 2010 — corneal wound healing improvement (topical Phase II)
- 3.Philp et al., Ann NY Acad Sci 2012 — cell migration and survival mechanism
Phase II trials were TOPICAL, NOT systemic injection as used in compounding practice. RegeneRx clinical program stalled/abandoned.
Cardiac regeneration research continues. Neurological repair (TBI, stroke) interest growing. Combination with BPC-157 popular in clinical practice.